A New Regulatory Mechanism Between P53 And YAP Crosstalk By SIRT1 Mediated Deacetylation To Regulate Cell Cycle And Apoptosis In A549 Cell Lines

References

• Ahmed AA, Mohamed AD, Gener M, Li W, Taboada E. YAP and the Hippo pathway in pediatric cancer. Mol Cell Oncol. 2017;4(3):e1295127. doi:10.1080/23723556.201728616573
   PubMedGoogle Scholar
• Zanconato F, Forcato M, Battilana G, et al. Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth. Nat Cell Biol. 2015;17(9):1218–1227. doi:10.1038/ncb321626258633
   PubMed Web of Science ®Google Scholar
• Panciera T, Azzolin L, Cordenonsi M, Piccolo S. Mechanobiology of YAP and TAZ in physiology and disease. Nat Rev Mol Cell Biol. 2017;18(12):758–770. doi:10.1038/nrm.2017.8728951564
   PubMed Web of Science ®Google Scholar
• Maugeri-Sacca M, De Maria R. The Hippo pathway in normal development and cancer. Pharmacol Ther. 2018;186:60–72. doi:10.1016/j.pharmthera.2017.12.01129305295
   PubMed Web of Science ®Google Scholar
• Piccolo S, Dupont S, Cordenonsi M. The biology of YAP/TAZ: hippo signaling and beyond. Physiol Rev. 2014;94(4):1287–1312. doi:10.1152/physrev.00005.201425287865
   PubMed Web of Science ®Google Scholar
• Sorrentino G, Ruggeri N, Specchia V, et al. Metabolic control of YAP and TAZ by the mevalonate pathway. Nat Cell Biol. 2014;16(4):357–366. doi:10.1038/ncb293624658687
   PubMed Web of Science ®Google Scholar
• Strano S, Fausti F, Di Agostino S, Sudol M, Blandino G. PML surfs into HIPPO tumor suppressor pathway. Front Oncol. 2013;3:36. doi:10.3389/fonc.2013.0003623459691
   PubMedGoogle Scholar
• Karpowicz P, Perez J, Perrimon N. The Hippo tumor suppressor pathway regulates intestinal stem cell regeneration. Development. 2010;137(24):4135–4145. doi:10.1242/dev.06048321098564
   PubMed Web of Science ®Google Scholar
• Cho E, Feng Y, Rauskolb C, Maitra S, Fehon R, Irvine KD. Delineation of a fat tumor suppressor pathway. Nat Genet. 2006;38(10):1142–1150. doi:10.1038/ng188716980976
   PubMed Web of Science ®Google Scholar
• Ryan KM, Phillips AC, Vousden KH. Regulation and function of the p53 tumor suppressor protein. Curr Opin Cell Biol. 2001;13(3):332–337. doi:10.1016/S0955-0674(00)00216-711343904
   PubMed Web of Science ®Google Scholar
• Dai C, Gu W. p53 post-translational modification: deregulated in tumorigenesis. Trends Mol Med. 2010;16(11):528–536. doi:10.1016/j.molmed.2010.09.00220932800
   PubMed Web of Science ®Google Scholar
• Harms KL, Chen X. The functional domains in p53 family proteins exhibit both common and distinct properties. Cell Death Differ. 2006;13(6):890–897. doi:10.1038/sj.cdd.440190416543939
   PubMed Web of Science ®Google Scholar
• Bai N, Zhang C, Liang N, et al. Yes-associated protein (YAP) increases chemosensitivity of hepatocellular carcinoma cells by modulation of p53. Cancer Biol Ther. 2013;14:511–520. doi:10.4161/cbt.2434523760493
   PubMed Web of Science ®Google Scholar
• Meng Z, Moroishi T, Guan KL. Mechanisms of Hippo pathway regulation. Genes Dev. 2016;30(1):1–17. doi:10.1101/gad.274027.11526728553
   PubMed Web of Science ®Google Scholar
• Hong W, Guan KL. The YAP and TAZ transcription co-activators: key downstream effectors of the mammalian Hippo pathway. Semin Cell Dev Biol. 2012;23(7):785–793. doi:10.1016/j.semcdb.2012.05.00422659496
   PubMed Web of Science ®Google Scholar
• Furth N, Bossel Ben-Moshe N, Pozniak Y, et al. Down-regulation of LATS kinases alters p53 to promote cell migration. Genes Dev. 2015;29(22):2325–2330. doi:10.1101/gad.268185.11526588988
   PubMed Web of Science ®Google Scholar
• Imai S, Armstrong CM, Kaeberlein M, Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature. 2000;403(6771):795–800. doi:10.1038/3500162210693811
   PubMed Web of Science ®Google Scholar
• Lin Z, Fang D. The roles of SIRT1 in cancer. Genes Cancer. 2013;4:97–104. doi:10.1177/194760191247507924020000
   PubMedGoogle Scholar
• Yi J, Luo J. SIRT1 and p53, effect on cancer, senescence and beyond. Biochim Biophys Acta. 2010;1804(8):1684–1689. doi:10.1016/j.bbapap.2010.05.00220471503
   PubMed Web of Science ®Google Scholar
• Mao B, Hu F, Cheng J, et al. SIRT1 regulates YAP2-mediated cell proliferation and chemoresistance in hepatocellular carcinoma. Oncogene. 2014;33(11):1468–1474. doi:10.1038/onc.2013.8823542177
   PubMed Web of Science ®Google Scholar
• Hata S, Hirayama J, Kajiho H, et al. A novel acetylation cycle of transcription co-activator yes-associated protein that is downstream of Hippo pathway is triggered in response to sn2 alkylating agents. J Biol Chem. 2012;287(26):22089–22098. doi:10.1074/jbc.M111.33471422544757
   PubMed Web of Science ®Google Scholar
• Liu X, Ehmed E, Li B, et al. Breast cancer metastasis suppressor 1 modulates sirt1-dependent p53 deacetylation through interacting with dbc1. Am J Cancer Res. 2016;6(6):1441–1449.27429856
   PubMed Web of Science ®Google Scholar
• Demchak B, Hull T, Reich M, et al. Cytoscape: the network visualization tool for genomespace workflows. F1000research. 2014;3:151. doi:10.12688/f1000research25165537
   PubMedGoogle Scholar
• Yamamori T, DeRicco J, Naqvi A, et al. SIRT1 deacetylates APE1 and regulates cellular base excision repair. Nucleic Acids Res. 2010;38(3):832–845. doi:10.1093/nar/gkp103919934257
   PubMed Web of Science ®Google Scholar
• Xiao W, Wang J, Ou C, et al. Mutual interaction between YAP and c-Myc is critical for carcinogenesis in liver cancer. Biochem Biophys Res Commun. 2013;439(2):167–172. doi:10.1016/j.bbrc.2013.08.07123994632
   PubMed Web of Science ®Google Scholar
• Yuan F, Liu L, Lei Y, Tang P. p53 inhibits the upregulation of sirtuin 1 expression induced by c-Myc. Oncol Lett. 2017;14(4):4396–4402. doi:10.3892/ol.2017.666128943955
   PubMed Web of Science ®Google Scholar
• Liu L, Scolnick DM, Trievel RC, et al. p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage. Mol Cell Biol. 1999;19(2):1202–1209. doi:10.1128/mcb.19.2.12029891054
   PubMed Web of Science ®Google Scholar
• Li M, Chen D, Shiloh A, et al. Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature. 2002;416(6881):648–653. doi:10.1038/nature73711923872
   PubMed Web of Science ®Google Scholar
• Kodaka M, Hata Y. The mammalian Hippo pathway: regulation and function of YAP1 and TAZ. Cell Mol Life Sci. 2015;72(2):285–306. doi:10.1007/s00018-014-1742-925266986
   PubMed Web of Science ®Google Scholar
• Mao B, Gao Y, Bai Y, Yuan Z. Hippo signaling in stress response and homeostasis maintenance. Acta Biochim Biophys Sin (Shanghai). 2015;47(1):2–9. doi:10.1093/abbs/gmu10925476206
   PubMed Web of Science ®Google Scholar
• Di Agostino S, Sorrentino G, Ingallina E, et al. YAP enhances the pro-proliferative transcriptional activity of mutant p53 proteins. EMBO Rep. 2016;17(2):188–201. doi:10.15252/embr.20154048826691213
   PubMed Web of Science ®Google Scholar
• Wang Z, Chen W. Emerging roles of SIRT1 in cancer drug resistance. Genes Cancer. 2013;4:82–90. doi:10.1177/194760191247382624019998
   PubMedGoogle Scholar
• Song NY, Surh YJ. Janus-faced role of SIRT1 in tumorigenesis. Ann N Y Acad Sci. 2012;1271:10–19. doi:10.1111/j.1749-6632.2012.06762.x23050959
   PubMed Web of Science ®Google Scholar
• Zhao Y, Lu S, Wu L, et al. Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1). Mol Cell Biol. 2006;26(7):2782–2790. doi:10.1128/MCB.26.7.2782-2790.200616537920
   PubMed Web of Science ®Google Scholar
• Rivlin N, Brosh R, Oren M, Rotter V. Mutations in the p53 tumor suppressor gene: important milestones at the various steps of tumorigenesis. Genes Cancer. 2011;2:466–474. doi:10.1177/194760191140888921779514
   PubMedGoogle Scholar
• Freed-Pastor WA, Prives C. Mutant p53: one name, many proteins. Genes Dev. 2012;26(12):1268–1286. doi:10.1101/gad.190678.11222713868
   PubMed Web of Science ®Google Scholar